Adoptive T cell therapy, including chimeric antigen receptor (CAR) T cells, has achieved significant success in targeted cancer cell eradication [1,2]. Although the FDA has approved CAR-T cell therapies for certain hematological malignancies, a significant proportion of patients relapse within one ye...